About us

Founded in 2017, Solstar Pharma has built a precision RNA interference (RNAi) platform that leverages years of research experience and unique insights into small interfering RNA (siRNA) nucleic acid medicine.


We have assembled a management team of biopharmaceutical experts with extensive experience in drug discovery, development, and commercialization.

Tom Rossi


Tom Rossi serves as President and Chief Executive Officer of Solstar Pharma Inc. Mr. Rossi has over 30 years of experience in the pharmaceutical and vaccine industries in Canada and abroad. Previously, he was the President and CEO of Acerus Pharmaceuticals Corp., a TSX-listed specialty pharma company focused on the development, manufacture and commercialization of innovative medicines. Prior to Acerus, Mr. Rossi held a variety of senior leadership positions within Novartis both in the Pharmaceuticals and Oncology divisions. While at Novartis, he served as CEO and Country President for Novartis Pharmaceuticals Canada, CEO and Country President for Novartis Pharmaceuticals Belgium-Luxembourg and General Manager Oncology in Canada.

Mr. Rossi joined Novartis from Merck Canada (Vaccine Division) and began his healthcare career with Johnson & Johnson.

Mr. Rossi received a Bachelor of Science degree in Microbiology and Immunology from McGill University and an MBA from the John Molson School of Business focused on Pharmaceutical Marketing.

Dennis Baltzis, PhD


Dennis Baltzis, PhD is a co-founder of Solstar Pharma Inc. and as its President from 2017 until November 2021. Mr. Baltzis now serves as the Chief Scientific Officer and is one of the members of the Board of Directors. Prior to joining Solstar, Mr. Baltzis spent 5 years monitoring, managing, and coordinating various phase I-III oncology clinical trials throughout Canada and the United States. Mr. Baltzis previously worked as an oncology clinical research

associate at Covance, and as an Oncology Clinical Research Coordinator at the Clinical Research Unit of the Jewish General Hospital, Montreal, Canada.


GF Mille Co. Ltd
(GFM) Agreement

GF Mille Co. Ltd. (GFM) is a Japanese research-based company developing precision nucleic acid medicines in collaboration with Gifu University.

GFM conducts basic research and preclinical studies in Japan primarily in the fields of oncology and virology.

Linear Therapies Inc.
(LTI) Agreement

Linear Therapies is a company focused on the research & development of antimicrobial, anti-viral, and anti-cancer agents for the treatment of life-threatening diseases. Linear Therapies is focusing on delivering a safe and immediate anti-infective agent specifically targeted at the COVID-19 pandemic.

B-Organic Films Corp.

B-Organic is a bio-chemical research company that concentrates on the development of molecular structures that have scientific or commercial value for industry partners in the Pharmaceutical, Nutraceutical and Agricultural sector.

B-Organic has developed and patented a simple and natural matrix to be used as a unique innovative excipient which is able to enhance bioavailability of several poorly soluble drugs, fatty acids, and vitamins and consequently to improve performance for numerous active pharmaceutical ingredients (APIs).